According to conclusions provided by the Drug Enforcement Administration, “In US markets, Mexican marijuana has largely been supplanted by domestic-produced marijuana.”
Patients in the treatment group experienced a decrease in pain of 29 percent over the course of the trial, whereas those in the control group only experienced a six percent decrease.
“Medicinal cannabis was associated with improvements in depression and anxiety symptoms, as well as health-related quality of life,” investigators concluded.
Authors reported, “For some demographic sub-groups, we find evidence of modest increases in employment or wages, particularly for … those working in the agriculture sector.”
Investigators concluded, “Cannabinoids have a role in treating chronic neuropathic pain.”